SoftBank Shares Plunge 11% After OpenAI Rules Out 2026 IPO 
Rosenblatt Starts Nokia at Buy on AI Networking Growth 
Trip.com Shares Rise as Q2 Earnings Beat Estimates 
Bill Gates Warns Governments Are Unprepared for AI Disruption 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
American Airlines Eyes Capacity Cuts as High Fuel Prices Persist 
US Court Approves airBaltic Chapter 11 Restructuring 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Cathie Wood Backs AI Slowdown as Safety Concerns Grow 
Qualcomm Gains on $60B Amazon AI Chip Deal 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Apple Pay Set for India Launch With Axis Bank 
MediaTek Unveils 2nm Dimensity 9600 Pro AI Chip 
SK Hynix, Intel Discuss U.S. Memory Chip Production Deal 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
France Urges Faster AI Push Despite Safety Risks 
Ex-Google DeepMind Researcher Warns AI Could Pose Existential Threat 
Add as a preferred source on Google
Pittsburgh, Nov. 08, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at the Lotte New York Palace Hotel.
Mr. Moch’s presentation will include a corporate update as well as summary of results from the company’s Phase 1b/2a study of CT1812 in patients with mild-to-moderate Alzheimer’s disease. These results, which were recently presented at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, showed that CT1812 was well tolerated and generated a differential change compared to placebo in the levels of several key cerebrospinal fluid proteins that are dysregulated in Alzheimer’s disease.
About CT1812
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Aβ) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Study COG0102 was supported in part under Award Number RF1AG054176 from The National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.
Cognition Therapeutics [email protected] 412-465-0095 Aline Sherwood Scienta Communications [email protected] 312-238-8957
